Drug Trial Radar · NCT01408069
Non-Inferiority Comparison of Migrane® Versus Parcel ® For Treatment of Tensional Cephaleia
Last checked: Nov 20, 2026Latest source record: Feb 24, 2021 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Withdrawn
Enrollment
0
Actual
Start
Not stated
Primary completion
Not stated
Sponsor
- Lead sponsor
- EMSIndustry
- Sponsor type
- Industry
- First posted
- Aug 3, 2011
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Triple (participant, care provider, investigator)
- Primary purpose
- Treatment
- Who can join
- All sexes, from 18 years, up to 65 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this study is to evaluate the non-inferiority clinical efficacy of two different associations of drugs in the treatment of patients diagnosed with tensional-type headache in accordance with International Headache Society guidelines.
Conditions
- Tensional-type Headache
Interventions
MIGRANEDrug
1 to 2 tablets(ergotamine 1mg + caffeine 100mg + acetylsalicylic 350 mg + homatropine 1,2 mg)
PARCELDrug
1 to 2 tablets(ergotamine 1mg + paracetamol 450 mg + caffeine 40 mg)
Primary outcomes
What the sponsor says the trial is designed to measure.
- Efficacy of treatment in relieve headache symptoms.Time frame: 1 hour
Locations
No sites are listed on the registry yet.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.